[사회]Interruption of the introduction of the vaccine to external variables? … Government “No changes”

[앵커]

AstraZeneca is the only vaccine for the prevention of COVID-19 that has been signed by the government.

However, news that the vaccine could be difficult to obtain FDA approval from the US Food and Drug Administration this year raised concerns that national introduction could hamper it.

The government said it is unlikely and stressed that there will be no changes to the security plan for the first half of next year.

This is reporter Hyungwon Lee.

[기자]

Even if the US Food and Drug Administration delays approval of the AstraZeneca vaccine, the government’s position is that it will not have a significant impact on the domestic market.

[이상원 / 중앙방역대책본부 역학조사분석단장 : 이것과 관련돼서 국내에서 어떤 도입이라든가 생산이 지체될 가능성은 현재로써는 좀 낮다고….]

If there are no serious side effects, it is believed that it will pass, but the approval or not and the national introduction are independent.

The Ministry of Food and Pharmaceutical Safety decides whether it should be used in Korea, and one of the factors to consider is whether or not the developing country of the vaccine should approve it.

[김상봉 / 식품의약품안전처 바이오생약국장 : (다른 나라 허가 여부에) 종속된 게 아니라는 건 맞지만, 미국 또는 유럽 이런 쪽에 긴급 사용 승인 사실 자체에 무관하게 처리하기도 어려운 상황입니다.]

The experts noted that the possible delay in FDA approval appears to be a combination of American interests and should be approached with caution.

This is not a problem of side effects, but the fact that there is no difference in efficacy or clinical results over 55 years is not a serious defect.

[이재갑 / 한림대 강남성심병원 교수 : 아스트라제네카가 다른 백신에 비해 부작용이 많다거나, 뭔가 문제가 있거나 이런 건 지금까지 간주한 게 아무것도 없거든요. 미국 자체가 자국 산업 보호 측면에서도 그런 식으로 얘기할 수밖에 없는 상황일 수도 있어서….] [백순영 / 가톨릭의대 명예교수 : (아스트라제네카는) 값도 3~4달러에 불과하기 때문에 엄청나게 경쟁력이 생겨버려요, 보관도 그렇고. 그래서 (미국 제약사인) 모더나나 화이자는 지금 초기에 다 소비하지 못하면 경쟁력이 없어져 버리잖아요.]

Meanwhile, it was confirmed that President Trump’s executive order for preferential vaccination for nationals was not related to obtaining domestic vaccines.

The government emphasized that the goal of introducing AstraZeneca in the first half of next year will remain unchanged, as it has already agreed that AstraZeneca’s domestic production volume will be supplied first.

YTN Hyungwon Lee[[email protected]]it is.

※ ‘Your report becomes news’ YTN is waiting for your valuable report.
[카카오톡] Search YTN to add a channel [전화] 02-398-8585 [메일] [email protected] [온라인 제보] www.ytn.co.kr

[저작권자(c) YTN & YTN plus 무단전재 및 재배포 금지]